Abraham Zadeh Andreas
Assisted Reproduction, Eugin Clinic, Carrer de Balmes, 236, Barcelona, 08006, Spain.
Reprod Biol Endocrinol. 2025 Aug 1;23(1):113. doi: 10.1186/s12958-025-01446-4.
The growing influence of private equity (PE) in reproductive medicine makes it increasingly important to examine its impact from the perspectives of physicians, patients, and investors. As PE firms increasingly acquire fertility clinics and related healthcare services, they bring promises of operational efficiency, expanded access, and innovation. At the same time, these developments have come under growing scrutiny, raising critical concerns about the commercialization of care, equity of access, and the long-term impact on clinical outcomes. From the physician's viewpoint, PE involvement presents both opportunities and challenges-shaping medical autonomy, clinical decision-making, and the ability to prioritize patient-centered care. The article critically assesses these dynamics, weighing the potential benefits of investment against concerns over profit-driven models, regulatory scrutiny, and the shifting role of healthcare professionals in an increasingly corporatized landscape.
私募股权（PE）在生殖医学领域的影响力日益增长，从医生、患者和投资者的角度审视其影响变得越来越重要。随着私募股权公司越来越多地收购生育诊所及相关医疗服务，它们带来了运营效率提升、服务可及性扩大和创新的承诺。与此同时，这些发展受到了越来越多的审视，引发了对医疗商业化、服务可及性公平性以及对临床结果长期影响的严重关切。从医生的角度来看，私募股权的参与既带来了机遇，也带来了挑战——影响医疗自主权、临床决策以及将以患者为中心的护理置于优先地位的能力。本文批判性地评估了这些动态，权衡了投资的潜在益处与对利润驱动模式、监管审查以及在日益公司化的环境中医疗专业人员角色转变的担忧。
